Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252535 | 1.00 | MAPT (0.38) | MAPTLMNAPIK3CDATMKMT2A | |
| SCHEMBL4173841 | 0.88 | KMT2A (0.38) | MAPTLMNAPIK3CDATMKMT2A | |
| SCHEMBL4173838 | 0.88 | KMT2A (0.38) | MAPTLMNAPIK3CDATMKMT2A | |
| SCHEMBL15336892 | 0.88 | KMT2A (0.38) | MAPTLMNAPIK3CDATMKMT2A | |
| SCHEMBL4191638 | 0.81 | PIK3CD (0.40) | MAPTPIK3CDATMKMT2AMEN1 | |
| SCHEMBL14870378 | 0.81 | EGFR (0.42) | MAPTLMNAPIK3CDKMT2ATDP1 | |
| SCHEMBL17718345 | 0.81 | EGFR (0.42) | MAPTLMNAPIK3CDKMT2ATDP1 | |
| SCHEMBL252602 | 0.81 | MAPT (0.35) | MAPTLMNAPIK3CDATMKMT2A | |
| SCHEMBL252601 | 0.81 | MAPT (0.35) | MAPTLMNAPIK3CDATMKMT2A | |
| SCHEMBL10285539 | 0.80 | KMT2A (0.34) | MAPTLMNAPIK3CDATMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834231-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2834231-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-8835432-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140206694-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8716290-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2013152150-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130267524-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2588469-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130096134-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2012003271-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267524-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | MAPT 3355/4885LMNA 2309/4885PIK3CD 16/4885 |
| US-20140206694-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | MAPT 3355/4885LMNA 2309/4885PIK3CD 16/4885 |
| US-20130096134-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, MALT1 | MAPT 2338/4885LMNA 2553/4885PIK3CD 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.